Evidence map›Paper›PMID 41801765›Full record

ArticleCancer science2026

Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC.

Charlène Thiebaut, Sébastien Martinez, Ludivine Pruvost, Louisane Eve, Rania El-Botty, Laura Sourd, Elodie Montaudon, Ahmed Dahmani, Heloise Derrien, Stéphanie Sentis and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Charlène ThiebautUniversité Claude Bernard Lyon 1, Lyon, France.
Sébastien MartinezUniversité Claude Bernard Lyon 1, Lyon, France.
Ludivine PruvostUniversité Claude Bernard Lyon 1, Lyon, France.
Louisane EveUniversité Claude Bernard Lyon 1, Lyon, France.
Rania El-BottyLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.
Laura SourdLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.
Elodie MontaudonLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.
Ahmed DahmaniLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.
Heloise DerrienLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.
Stéphanie SentisUniversité Claude Bernard Lyon 1, Lyon, France.
Coralie PoulardUniversité Claude Bernard Lyon 1, Lyon, France.
Elisabetta MarangoniLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.
Olivier TrédanUniversité Claude Bernard Lyon 1, Lyon, France.
Muriel Le RomancerUniversité Claude Bernard Lyon 1, Lyon, France.ORCID https://orcid.org/0000-0002-8491-4015

Funding

Fondation ARC pour la Recherche sur le CancerFondation de FranceITMO Cancer of AviesanLigue contre le cancer comité de saone et Loire
6 · The paper itself

Abstract

Patients with triple-negative breast cancer (ER

Indexed as

Antineoplastic AgentsDNA Breaks, Double-StrandedDNA RepairProtein-Arginine N-MethyltransferasesRepressor ProteinsTriple Negative Breast NeoplasmsAnimalsCarboplatinCell Line, TumorCell ProliferationDoxorubicinFemaleHumansAntineoplastic AgentsCarboplatinDoxorubicinPRMT1 protein, humanPRMT5 protein, humanProtein-Arginine N-MethyltransferasesRepressor Proteinsarginine methylationDNA‐damage repairPRMT1PRMT5triple‐negative breast cancer

Identifiers

PMID41801765
PMCPMC13134520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.